AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
188 hedge funds and large institutions have $1.49B invested in Aimmune Therapeutics in 2020 Q3 according to their latest regulatory filings, with 85 funds opening new positions, 29 increasing their positions, 53 reducing their positions, and 60 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
14% less call options, than puts
Call options by funds: $33.2M | Put options by funds: $38.7M
45% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 53
Holders
188
Holding in Top 10
9
Calls
$33.2M
Puts
$38.7M
Top Buyers
| 1 | +$86.2M | |
| 2 | +$71.5M | |
| 3 | +$66.3M | |
| 4 |
Goldman Sachs
New York
|
+$65.1M |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
+$39M |
Top Sellers
| 1 | -$114M | |
| 2 | -$88.1M | |
| 3 | -$79M | |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$71.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$57.9M |